Virbac Animal Health has launched a broad spectrum wormer for dogs called Endogard (praziquantel, pyrantel and febantel).
Virbac says Endogard offers treatment against most types of intestinal worms found commonly in dogs. It is presented in two tablet sizes for easy dosage.
Victoria Hudson, Product Manager for Endo and Ectoparasiticides, said: "While we're known for developing innovative products which help practices generate additional revenue streams, we can also support them by offering cost-effective and proven products for routine use.
Endogard is a perfect example. The efficacy of its active ingredients is well-established; it's simple for owners to administer and it's also affordable which will bring them back to the practice. It's an excellent addition to Virbac's strong range of parasite control treatments."
For further information, contact your Territory Manager or call Virbac on 01359 243243.
Burgess Excel has extended its range with what it claims is the UK's most absorbent paper bedding for rabbits, guinea pigs and chinchillas, and a new 'sensitive' variety of nuggets for rabbits and guinea pigs.
Burgess says the bedding is made from environmentally-friendly high quality virgin wood pulp which locks away moisture and liquids quickly and securely. The company also highlights the fact that it is made using advanced, specialised drying and dust extraction techniques to prevent respiratory problems and eye infections which can occur when there is a large amount of dust present in a fibrevore's environment.
The new rabbit and guinea pig nuggets contain 46% Beneficial Fibre with a grain free recipe for delicate digestive systems.
To find out more about the new products, visit www.excelfeedingplan.com/ or contact 0800 413 969.
Colonel Neil Smith has been elected Vice-President of the Royal College of Veterinary Surgeons. He takes up office at RCVS Day on 6 July 2012.
Neil graduated from the Royal Veterinary College in 1989, and was commissioned into the Royal Army Veterinary Corps (RAVC) with the intention of staying for four years. Twenty-two years later, he is now the Director Army Veterinary and Remount Services, effectively the Chief Veterinary Officer for the Army and head of the RAVC, which currently has over 35 Veterinary Officers.
He has held a mixture of clinical, staff and command positions, and has worked in the UK, US and Germany. He has Masters' Degrees in Food Science, Defence Administration and Defence Studies. He has also worked part-time in small animal practice (including the Blue Cross, of which he is now a Trustee), and was heavily involved in the Foot and Mouth Disease outbreak in 2001.
First elected to Council in 2004, Neil was re-elected in 2010 after a short break. He has served on Education, Advisory, Preliminary Investigation and Planning and Resources Committees, and on VN Council (currently Vice-Chairman and Chairman of the Awarding Body).
He has also previously been President of the RVC Student Union Society, the RVC Alumnus Association, Southern Counties, and the Association of Government Veterinarians. He is currently a Council member of the Central Veterinary Society, and has previously sat on the BVA's Veterinary Policy Group.
Neil said: "I am honoured to have been elected as the next Vice-President. The College is about to go through some significant organisational changes, not least because of the proposed legislative reform order. However, I aim to ensure that we remain focused on our primary role in safeguarding the health and welfare of animals committed to veterinary care. The functions of the RCVS are quite diverse, and I am keen that we try to enhance both the profession's and the public's understanding of our remit, including our responsibility for educational, ethical and clinical standards."
Jacqui Molyneux has been confirmed as President, and Dr Jerry Davies as Vice-President, effective July 2012.
Eurovet Animal Health has launched Thyforon Flavoured (levothyroxine sodium, POM-V), which replaces the company's canine hypothyroid treatment Forthyron.
Eurovet says that Thyforon Flavoured has the same clinical efficacy of Forthyron and veterinary surgeons won't need to make any dose adjustments when transitioning to the new product.
However, Thyforon Flavoured, with its palatable formulation, now offers the benefit of being voluntarily accepted by over 70 per cent of dogs in taste trials1. In addition there is a new 800 mcg formulation which gives more prescribing options, particularly for the treatment of large and giant breeds.Thyforon Flavoured comes as easy-break tablets to make dose adjustment straightforward, in an easy-to-dispense blister pack.
Thyforon Flavoured is available now - the person responsible for placing the practice drug order should just ask for Thyforon Flavoured when placing the next drug order and where appropriate, the practice management system should be updated to reflect the new name.
Reference1. Eurovet Animal Health Internal Study report, acceptance study, November 2011
Animalcare has launched Emdocam (meloxicam 20mg/ml), a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class for use in cattle, pigs and horses.
According to the company, Emdocam disrupts the inflammatory cascade by inhibiting prostaglandin synthesis. It is a potent and preferential inhibitor of COX-2, permitting sufficient COX-1 sparing activity. It has analgesic and anti-inflammatory effects. When administered in a single dose to cattle, it has long acting anti-endotoxic, anti-pyretic and anti-inflammatory effects for up to three days.1,2
In cattle, it is indicated for bovine respiratory disease (BRD), clinical mastitis and calf scour. Animalcare says early use of meloxicam for BRD reduces pyrexia and pain, especially in young calves and improves feed intake. Meloxicam plus an antibiotic significantly reduced the extent of lung lesions, leading to improved clinical efficacy and daily liveweight gain in comparison with animals treated with antibiotics alone, for example oxytetracycline,3 florfenicol4and tilmicosin. 5
In the case of clinical mastitis, Animalcare says that used adjunctively with an antibiotic, Emdocam helps relieve local and systemic inflammation, returns the udder to a normal condition and reduces the polymorphonuclear leucocytes (PMN) response. In a large scale, double-blinded study in New Zealand, the addition of meloxicam to antibiotic therapy resulted in lower Somatic Cell Counts and a reduced risk of culling in dairy cows with mild clinical mastitis.6
Calf scour treated with meloxicam, as a supportive therapy, can improve calf well-being and reduce morbidity. In a double-blinded, controlled study, the use of meloxicam improved daily water and feed intake, added greater average bodyweight (bw) gain and helped calves to wean earlier. 7
In horses, administered IV at 3.0ml/100kg bw, Emdocam can be used for musculo-skeletal disorders, as well as colic, resulting in reduced pain and inflammation. In a study of 18 horses comparing flunixin with meloxicam and designed to determine the effect on recovery of ischemic-injured jejunum, meloxicam was found to be a useful alternative for the post-operative treatment of colic. 8
Emdocam is also indicated in pigs for non-infectious locomotive disorders and as an adjunctive therapy with an antibiotic in puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome).
Tony Liepman from Animalcare said: "Emdocam is competitively priced whether used on its own or adjunctively with a long-acting intramuscular (IM) antibiotic, such as Florgane suspension for the treatment of BRD in calves. This, coupled with its long lasting, low volume (2.5ml/100kg bw in cattle), single dose administration, by intravenous (IV) or subcutaneous (SC) injection, makes Emdocam a highly efficacious and practical NSAID."
Emdocam is a POM-V medicine and available as 50 and 100ml multi-dose vials. Withdrawal period in cattle for meat and offal is 15 days and in pigs for meat and offal is 5 days. In horses for meat and offal it is 5 days. In Florgane [POM-V], the withdrawal period for meat and offal is 37 days in cattle and not to be used in cattle producing milk for human consumption
References
Cattle
Research carried out by the Kennel Club to coincide with Mother's Day has revealed that 35% of dog buyers do not see their new puppy with its mother.
The research also found that one in ten buyers take their puppy home before it is eight weeks old, and that 55% do not see the puppy in its breeding environment.
Bill Lambert, Manager of the Kennel Club Assured Breeder Scheme, said: "March is the most popular month for searching for a puppy, but we are extremely concerned that so many are not seeing their puppy with its mother. Seeing mum not only helps people to find out how their puppy will be likely to turn out in terms of temperament and characteristics, but it also gives them the reassurance that it has been bred in a loving environment where it has been cared for and socialised properly."
Marc Abraham, TV vet and Kennel Club Veterinary Advisor, said: "Puppies depend on their mums in the early weeks of life, not just for milk but she's also critical for developing their socialisation skills which help set them up for life. If a breeder refuses to show the puppy with its mother without very good reason, then buyers should go elsewhere."
The Kennel Club is urging people to see puppies with their mother as part of its Stop Puppy Farming campaign and is joining with Marc Abraham to support the 'Where's Mum?' campaign. Kennel Club research has shown that as many as one in four could unwittingly be buying their puppy from a puppy farm.
The Kennel Club will be running a National Puppy Awareness Week (PAW) from the 8th - 14th September. To find out more visit www.thekennelclub.org.uk/stoppuppyfarming.
Supreme Petfoods has announced that Think Rabbit Fortnight, a campaign to help practices engage with rabbit owners, will run from Monday 21st May to Friday 1st June.
Practices can decide how much they wish to participate in the campaign and can opt to receive goodie bags, a 'Think Rabbit' manual detailing how the practice can be more rabbit-friendly, or take the 'Small Furry' Promise.
The event is being backed by RCVS Exotics Specialist, Molly Varga. She said: "I'd encourage all practices to take part in Think Rabbit Fortnight to help improve the health and welfare of the nation's rabbits."
Supreme says that practices which take part in the Think Rabbit Campaign will also have the opportunity to sign up for Level 1 of its 'Better for Bunnies, Better for Business' programme, which it says can double turnover derived from rabbits through an increase in new clients, average visit transaction spend and attendance rates of existing clients.*
Claire Hamblion, Marketing Manager at Supreme says she hopes that it will really encourage practices to focus on how they can develop protocols and routines that will remove barriers to rabbit owners seeking healthcare advice and presenting their pet for treatment.
Binky - voted Britain's Cutest Bunny - will play a starring role in the Think Rabbit campaign to attract the attention of rabbit owners who will also be asked to nominate their rabbit as a VIP (Very Important Pet). Claire said: "Our VIP won't necessarily be the most prettiest, fastest or cleverest bunny but one that has special qualities in the eyes of its owner. I hope vets and nurses will help spread the word and maybe even nominate some very important patients."
To sign up for Think Rabbit Fortnight, visit www.supremepetfoods.com/thinkrabbit, email thinkrabbit@companionconsultancy.com, or telephone 01284 761107.
*Supreme - Better for Bunnies, Better for business programme, Onswitch March 2012
The Federation of European Companion Animal Veterinary Associations (FECAVA) has launched the European Journal of Companion Animal Practitioners (EJCAP) Online, the first European fully online veterinary journal.
As the official journal of the FECAVA, the EJCAP online is exclusively available to members of national companion animal veterinary associations which are in turn members of FECAVA (which include the BSAVA).
According to FECAVA, the EJCAP online will continue to offer the sort of high quality CPD articles which the magazine was known for during its 21 year history in print. However it will now also be able to offer rich media, such as videos with clinical presentations, endoscopy and ultrasound recordings, diagnostic and surgical techniques, interviews with experts, conference presentations as well as slide shows, interactive quizzes, surveys and animations.
The frequency of publication has also been increased, from three to four issues per year, including one special issue.
The EJCAP online is available in two languages - English and Spanish. More languages are planned in future.
Simon Orr, FECAVA president, said: "Since the momentous decision to publish EJCAP online was taken by our Council in Lille in 2009, we are delighted to offer our members this new and engaging way to gain new information and skills.
As we start work on the next issues, we invite all our readers to give us feedback on this first volume of EJCAP online. On the last spread (page) there is a link to a survey on this new format, to help us further improve and optimize EJCAP online."
To register, visit EJCAP online (www.fecava.org/ejcap).
Clinicians at the Queen Mother Hospital for Animals at the Royal Veterinary College have become the first team in the UK to successfully treat acromegaly in a cat with hypophysectomy surgery.
According to the RVC, this make it the first centre in the UK, and only the fourth in the world, to offer this procedure. The patient groups that might benefit from this RVC-exclusive procedure include cats and dogs with non-functional pituitary tumors, cats and dogs with hyperadrenocorticism (Cushing's disease) and cats with acromegaly or hypersomatotropism.
The RVC says removing the pituitary gland and the associated tumour which causes acromegaly or hyperadrenocorticism is the gold standard treatment in humans suffering from these diseases since it offers the greatest chance of a complete cure for the disease.
Prior to the RVC offering surgical treatment, the only treatment options available for acromegalic cats in the UK were radiation therapy or simply treatment of the resulting diabetes mellitus. The latter can prove extremely difficult and frustrating and the former unpredictable, unreliable and/or ineffective. Even when a complete response to the radiation therapy eventually occurs, hormonal abnormalities usually persist.
Dr Stijn Niessen, leading the hypophysectomy team at the Royal Veterinary College, said: "I'm extremely proud to be able to offer this unique surgery for the first time in the UK at the RVC. As a relatively new and innovative procedure in veterinary medicine there are risks involved, as is recognised with every form of neurosurgery of this level. However, despite these risks, this surgery does offer owners a chance for the best possible result for their pet using a single procedure. Hypophysectomy therefore represents the most elegant treatment method currently available enabling complete removal of the brain tumor and normalisation of damaging excessive hormone levels that are causing hormonal diseases like acromegaly and hyperadrenocorticism.
"Especially when a pituitary tumor is diagnosed late, the alternative treatment method of radiation therapy might well take too long to take effect and devastating neurological signs might occur due to the pressure of the pituitary tumor on the surrounding brain. In such cases, hypophysectomy can make an instant difference in relieving that pressure. However, in general, we would advocate the procedure to be considered as soon as possible following diagnosis, thereby preventing the animal's body from becoming more and more negatively affected by the excessive hormone levels associated with pituitary diseases like acromegaly and hyperadrenocorticism."
Dr. Niessen, a European Veterinary Specialist in Internal Medicine with research interests in diabetes and endocrinology and world-expert in acromegaly, will be selecting the patients suitable for the new treatment, preparing them for surgery and managing the aftercare programme. The longer-term aftercare programme will include hormone replacement treatment administered through eye-drops (usually temporarily) and tablets (permanent) to manage the hormone production lost through removal of the pituitary gland.
The surgery itself will be performed by Patrick Kenny, a European and American Specialist in Veterinary Neurology and Neurosurgery.
The RVC says the surgery would not be possible without the multidisciplinary approach at the Queen Mother Hospital for Animals, which includes the Internal Medicine, Neurology and Neurosurgery, Diagnostic Imaging, Anaesthesia and Emergency and Critical Care teams as well as a team of highly qualified nurses.
To support ongoing research in this field, the Royal Veterinary College is offering free blood tests for all diabetic dogs and cats which include fructosamine evaluation and screening tests for the presence of acromegaly in cats. Cats that record high hormone levels indicative of acromegaly will qualify to undergo a free CT scan for confirmation. If acromegaly is confirmed, all possible treatment options will be discussed with the client, including the hypophysectomy procedure. To request a free blood test for a patient please visit: www.rvc.ac.uk/cic
Veterinary surgeons currently managing a cat or dog with a pituitary tumor who are considering referral of this case can also contact Dr Stijn Niessen for further information at the QMHA on 01707 666365 or at qmhreception@rvc.ac.uk
A Europe-wide survey has found that speed and accuracy are the key features that farm animal veterinary surgeons and farmers want from diagnostic tests
More than 334 individuals from 8 countries were asked about their current usage and knowledge of diagnostics, and asked what they would like to see in the future. Greater accuracy was the number one need among veterinary surgeons, mentioned by 37%, followed by more speed (22%); cost savings (16%) and greater confidence in the results (8%) were other features that they would like to see improved.
The survey, which was commissioned by global biotechnology company Life Technologies, showed that most test results are currently available in one to three days, but still a significant proportion have to wait three to six days for results (39%) or even more than six days (20%). Only 10% currently get their results within 24 hours.
Although many of the vets were aware of modern molecular diagnostics tests such as PCR (polymerase chain reaction) which generally offer quicker results than culture testing, most did not know which were used most often. The vast majority of farmers were happy to leave the decision on type of diagnostics test to their veterinarian.
Frederic Bar, Sr. Marketing Manager EMEA at Life Technologies said: "The results show that veterinarians are looking for the speed and accuracy that modern molecular diagnostics, such as PCR, can provide, but this technology is still not being used as widely as it could be."
"One way in which veterinarians could get faster, more accurate-results would be to specify PCR when they submit samples to diagnostic laboratories.
"Diagnostics have really moved on in recent years and the modern tests can give very reliable results, often in just one day, so veterinarians and farmers can make herd health decisions more quickly."
The survey found that BVD, IBR and MAP tests were the most commonly used in cattle, while PRRS, Influenza A and Salmonella topped the list for swine. For sheep and goats, Salmonella, MAP and Chlamydia were the most frequently mentioned tests; for horses, EHV, equine infectious anaemia and Salmonella were most common. Avian influenza was by far the most commonly tested disease in poultry.
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
BCF has announced a number of special deals available on a variety of ultrasound and X-ray products.
With the launch of the new Mindray DP-50 ultrasound scanner, available exclusively from BCF, the company is offering a free trolley and a year's supply of gel.
If you buy a Carestream Vita CR X-ray system and generator from BCF, the company will update your X-ray protection with 3 gowns and 2 thyroid protectors (worth £600, €750) free.
Purchase an Easi-Scan with one battery, and you'll get a second battery and carry bag for free.
Buy an equine DR X-ray system and you'll receive £1,000 (€1,250) to spend on Podoblocks accessories.
Call +44 (0)1506 460 023 or visit www.bcftechnology.com for further information. Offers valid until 31st June.
Edinburgh-based charity the Global Alliance for Livestock Veterinary Medicines (GALVmed) has announced three drug discovery contracts in an effort to combat animal African Trypanosomosis (AAT), a disease which is estimated to cost Africa US$5billion a year.
Animal African trypanosomosis, transmitted by the tsetse fly, is a parasitic disease which affects livestock, resulting in a chronic illness which often ends in death. An estimated 50 million cattle and 70 million sheep and goats are at risk, with around 3 million cattle dying annually from the disease.
AAT causes economic losses in livestock, reducing meat and milk production and leaving animals so weak they are unable to help cultivate land. It affects over 10 million square kilometres of fertile land spread across nearly 40 countries in Africa and therefore has a huge impact on food and nutritional security and livelihoods across the continent.
The drugs that are currently used were developed in the 1950s and 60s and drug resistance is now a commonly reported problem. With few other options available, these drugs are the most important method of controlling the disease.
In May 2011 the Department for International Development (DfID) awarded GALVmed 30 month grant for £8million to facilitate the development of drugs, diagnostics and potential vaccines for the control of AAT.
The first contract was awarded to Anacor Pharmaceuticals Inc., a California based biopharmaceutical company established in 2002.
As part of a Drugs for Neglected Diseases Initiative (DNDi) supported project, Anacor and their partners discovered a series of compounds to combat the human form of AAT, Human African Trysanosomsis (HAT). A number of compounds produced under this programme have properties which could make them suitable for the treatment and prevention of animal AAT. These relevant compounds will now be screened for efficacy and safety under the GALVmed contract.
The second and third contracts have both been awarded to the College of Life Sciences at the University of Dundee, one of Europe's top-ranked universities for life science research.
Dr Kevin Read, who is Head of Drug Metabolism and Pharmokinectics at the drug Discovery Unit is leading a piece of drug discovery and development research, which aims to develop new drugs for the treatment and possible prevention of AAT in cattle, and also a diagnostic test for use in the field. This builds on the university's work on HAT and drugs that were unsuitable for human treatment are now being re-evaluated as potential drugs for cattle.
Dr Read said: "I am very excited to be working in partnership with GALVmed to apply our extensive drug discovery expertise in HAT to identify and bring forward new potential drugs for the treatment and prevention of AAT. The new project offers an exciting opportunity to reposition compounds showing great promise for the treatment of first stage HAT into AAT, thus improving food security in some of the poorest countries in sub-Saharan Africa."
Woodley Equipment Company has launched RapidVet-H IC a testing kit for identifying blood types in cats and dogs.
RapidVet-H IC uses immuno-chromatographic technology to identify the feline blood groups: Type A, Type B and Type AB, and the canine blood groups: DEA 1.1 Negative and DEA 1.1 Positive
According to Woodley, this is the first such system to present a positive result as a red line on a white background, thus making it very easy to read.
RapidVet-H IC consists of a hand-held device containing three membranes and uses a diluent specific for these tests. It uses whole blood, or packed red blood cells. It is a cell capture assay, so patients exhibiting auto-agglutination or low PCV can be typed. The system displays results in 5-10 minutes.
For more information about RapidVet-H IC, email: sales@woodleyequipment.com, or call Woodley on +44 (0) 1204 669033 Option 1.
Ceva Animal Health has added a new module to its Cardio Academy website which will provide practical advice on the management of dilated cardiomyopathy in practice.
The module contains an interactive seminar hosted by leading cardiologist and professor of medicine and cardiology at North Carolina State University, Clarke Atkins. The seminar lasts around 30 minutes, after which you're are invited to answer quiz questions relating to the presentation in return for a CPD certificate.
Small animal product manager, Fraser Broadfoot, said: "Our online Cardio Academy is an extremely popular CPD resource that can be accessed at any time, day or night! By using leading specialists, the interactive seminars provide cutting edge and practical advice on a variety of cardiology subjects. We add a new module every month, so check the website regularly."
To access the Cardio Academy please visit www.cardioacademy.cevalearn.com.
Electoral Reform Services (ERS), the independent body that carries out the Royal College of Veterinary Surgeons' Council election, has offered reassurance that the election was fair, in spite of a number of voters being sent duplicate ballot papers.
According to the College, ERS designs and prints the ballot papers, and receives back votes via the post, internet and text message, but it does not distribute the ballot papers: this was carried out by a separate mailing house contracted directly by the RCVS. Although the exact number of voters who received duplicate papers is not known, it may have been up to 289, as that was the shortfall of voting papers at the mailing house.
ERS carried out a review of voting patterns, including issues such as multiple votes coming from a single IP address, and concluded that it was not possible to say there had been instances of dual voting. Even in the small number of cases where there was a suggestion of dual voting, if those particular votes had been discounted it would not have affected the outcome of the election.
In a letter to the College, Adrian Wilkins, ERS Senior Consultant said: "Our view is... that although a number of members were sent two ballot papers, there is no firm evidence of fraud, and that the result is an accurate reflection of the views of the members of the Royal College. Our recommendation is consequently that the result should be declared as per our election report of 30th April 2012."
As a consequence, the RCVS returning officer, Gordon Hockey, Acting Registrar, declared the election results on 30 April.
The RCVS has announced that its former President, Professor Sandy Trees, will be appointed to the House of Lords as a non-party-political (cross-bench) peer, following recommendation by the House of Lords Appointments Commission.
Professor Trees, who was President of the RCVS in 2009-2010, has served on the College Council for 12 years. He becomes only the second veterinary surgeon to take a seat in the House of Lords, joining Lord Soulsby of Swaffham Prior.
Professor Trees said: "This is a great honour, and a wonderful opportunity. I look forward to the prospect of ensuring that legislation relating to animal health and welfare is fit for purpose, but I also feel that veterinary surgeons have a great deal to offer society more broadly, and I will relish the opportunity of raising the profile of the profession and what it can contribute.
"Beyond the immediate veterinary sphere, my areas of experience include science, the environment, education, middle eastern politics and tropical medicine, so I hope to be able to contribute to the work of the House of Lords on many fronts."
Dr Jerry Davies, RCVS President, said: "I am delighted to hear that Professor Sandy Trees has been appointed to the House of Lords. I know that he will not only represent the profession on all matters of veterinary science, veterinary education, animal welfare and public health, but as a cross-bencher, he will also bring a breadth of experience to bear on issues outside the immediate interests of our profession. He is a well informed and articulate advocate of whom the profession can be rightly proud."
The BVA also welcomed the appointment. BVA President Carl Padgett said: "The British Veterinary Association is absolutely delighted at Professor Trees' appointment to the House of Lords. He will bring a wealth of experience and scientific expertise into the political arena, not only in the fields of animal health and welfare but also public health, where he has particular knowledge and experience.
"We are pleased that the value of veterinary input in legislative debate has been recognised by the Appointments Commission.
"We are also proud that Professor Trees will be formally opening this September's BVA Congress in Liverpool where he inspired two generations of vets through his teaching and research, and we look forward to working with him to deliver a healthy future for animals, vets and the country."
MSD Animal Heath has launched a new dispensing pack to help veterinary practices develop retail sales for Cosequin DS, the joint supplement for pets.
The new dispensing pack, which doubles up as a display pack, contains 300 chews foil-wrapped for extra freshness in 30 packs of 10 strips, allowing Cosequin to stand in the waiting room or on reception.
The new pack, available now in wholesalers, replaces the previous 90, 120 and 180 DS chewable tablet pack sizes.
Burgess Excel has announced the launch of a new app for Android and Apple devices called The Fibrevore Handbook.
The free app, which is available from Apple here, and from Google for Android here, contains a guide to the veterinary care of rabbits, guinea pigs and chinchillas:
In addition the Fibrevore Handbook contains links to a range of Academic Articles, CPD courses and information on Burgess Excel and its products.
Burgess says the app will be updated on an on-going basis with further research findings, articles, images and general information
The British Veterinary Association has launched a survey of its members: "Your BVA, Your Say".
The focus of the research, which will take place throughout June and July, is to measure and evaluate the levels of satisfaction BVA members have with the Association and examining the value members place on BVA's representative role and benefits package.
A selection of members will be contacted by the external research agency Research by Design to take part in in-depth interviews to explore key themes of the research. Members who are currently practising and those in their final year at veterinary school will then be asked to complete an online survey.
Ahead of the research BVA is urging members to check that the Association has their most up-to-date contact details by visiting the member area of the website www.bva.co.uk/member or contacting the membership team on 020 7908 6350.
The results of the research will be used to develop and adapt BVA member services, activity and communication to ensure the Association meets members' requirements throughout their careers.
BVA President Carl Padgett said: "Our members are at the heart of everything we do, so it is essential we hear directly what our members think about, and want from, their Association.
"I'd like to encourage members to find time to contribute their ideas and opinions which will shape the future direction of the BVA. This is the chance to really make a difference to the Association."
The Feline Advisory Bureau (FAB) has announced the winners of four 'Easy to Give' Awards, given to the makers of veterinary medicines designed to be easy to administer to cats.
Claire Bessant, FAB's Chief Executive, said: 'Medicating cats is notoriously difficult. It is, therefore, always a pleasure to be able to reward companies who have made great efforts to make their products easier to administer to cats'.
The 2012 FAB Easy to Give Award winners were:
ALSTOE: Therios - The antibiotic cephalexin as a palatable tablet that can be split easily for accurate dosing in cats.
VIRBAC: Effipro - A spot-on preparation for the treatment of fleas, ticks and lice. The new transparent pipette prevents spillage and ensures a complete dose is given. An image of a cat appears on each pipette, so that if one is separated from its packaging it is still clear for which animal the product is intended.
NOVARTIS: Atopica - A treatment for allergic dermatitis that comes in solution form and can be given in food or directly into the cat's mouth. The specifically-designed syringe dispenser allows accurate dosing.
CEVA: Fiprospot - A spot-on medication for treating fleas and flea allergic dermatitis.
The winning products join 20 others which have been given an Easy to Give Award by FAB's expert panel of veterinary surgeons since 2005.
For more information about FAB, visit: www.fabcats.org
Novartis has made a last call for entries to its competition in which you can win an iPad whilst getting the latest update on the correct use of NSAIDs from an acknowledged expert in the field.
To enter the competition, watch the first in a series of webcasts by Dr Jo Murrell, Senior Lecturer at Bristol Vet School, then answer three questions about what you've seen.
Competition closes at the end of May. More information here.
A study carried out at the University of Leicester's School of Psychology has found that disagreeable younger people are more likely to prefer aggressive dogs, confirming the conventional wisdom that dogs match the personality of their owners.
Researchers found that low agreeableness was the best predictor of a preference for those dogs seen as more aggressive, such as bull terriers or boxers. Individuals low in agreeableness are typically less concerned with others' well-being and may be suspicious, unfriendly and competitive.
However, the study found no link between liking an aggressive dog and delinquent behaviour, or the possibility that liking an aggressive dog is an act of 'status display' to show off or attract romantic partners.
Dr Vincent Egan, lead researcher on the study, said: "This type of study is important, as it shows assumptions are not the whole picture. It is assumed owners of aggressive dogs (or dogs perceived as aggressive) are antisocial show-offs. But we did not find persons who expressed a preference for aggressive dogs had committed more delinquent acts, or reported showing off more.
"However, we did find a preference for a dog with an aggressive reputation was related to being younger and being lower in agreeableness (i.e., being less concerned with the needs of others, and being quicker to become hostile)."
The study looked at the reasons why some people prefer aggressive dog breeds. Professor Egan explained: "A lot of human behaviour involves status display and dominance, and evolutionarily this helps with finding mates. Basic personality also influences a lot of our behaviour. By measuring both at the same time, we could see whether they each had an influence on liking aggressive dogs, or whether one was due to another.
"We were surprised mating effort did not have an influence here, but think it might be because we looked at a wider age range. A preference for a non-aggressive dog may also make a statement about a person; liking a pedigree Labrador or a clipped Poodle may be as much a statement as having a pit-bull with a studded collar."
In the study, participants indicated their preference for different types of dogs, and filled in personality tests. The dogs were independently rated according to how aggressive people perceived them to be. Bull terriers were rated as most aggressive, followed by boxers; retrievers and cocker spaniels were seen as least aggressive.
Analysing the findings, the research team found that certain personality factors indicated a preference for dogs perceived to be more aggressive. Low agreeableness and higher conscientiousness were related to a preference for aggressive dog breeds. Younger people were also more likely to prefer the aggressive breeds.
Surprisingly, the results indicated a small effect suggesting that those who liked aggressive dogs showed signs of conscientiousness - being careful, reliable and thoughtful about their actions. This contradicts the perception that owners of aggressive dogs are always irresponsible.
Dr Egan said: "These results with conscientiousness were unexpected, but the effect is a small one, and needs to be repeated in a different group of people. Studies of this kind tend to only look at a restricted age ranges, which may exaggerate findings which do not occur across the entire lifespan, so we believe a stereotype is always true, whereas it may only be true under certain conditions. Our study employed a broader age range.
"We were surprised to find a small association between a preference for aggressive dogs and greater conscientiousness (i.e., valuing and following rules). However, dogs also prefer rules and firm boundaries themselves. We speculate that cheap dog-training classes would be enjoyable and beneficial for both dog and owner."
The findings were published last week in the journal Anthrozoos.
Dechra Veterinary Products has launched a case study competition to find out how veterinary professionals are using Celox, its new haemostatic agent designed to stop heavy bleeding.
According to the company, Celox Veterinary forms a gel-like clot within 30 seconds when mixed with blood.
Dechra says it would like examples of how it has been used, whether for planned procedures or in an emergency, and is asking veterinary surgeons and nurses to send in case histories and photos for the chance to win an iPad2.
Rachel Horton, Dechra's Brand Manager for Woundcare, said: "Celox Veterinary was launched to the market last year, with the human version of the product being used with great success on the battlefield by the British military for several years.
"Now we are asking veterinary professionals to share their experiences of using Celox Veterinary in practice, whether used in its gauze or granular form. It is ideal for fast-acting haemostasis, and provides a quick and efficient solution wherever and whenever bleeding needs to be stopped fast.
"Entrants providing case histories with accompanying photos can enter as many times as they like and have a chance to win an iPad2. Learning about how veterinary professionals are using products is important to Dechra Veterinary Products and assists in developing the high level of support we offer to vets and vet nurses."
Dechra says Celox Veterinary is being used not only for trauma injuries and emergency first aid but also for planned operations including castration, mass removal, nasal polyps, dental extractions and soft palate resections.
Case histories should be emailed to Rachel.Horton@dechra.com before the closing date of July 20th 2012 to be eligible for the draw. For further information about Celox Veterinary, please visit see www.dechra.com
The Royal Veterinary College is calling for dogs diagnosed with osteoarthritis to take part in a revolutionary study in which their movement will be monitored by a state-of-the-art recorder.
The recorder (pictured right), which is attached to the dog's collar, uses miniaturised sensors based on those found in smart phones. It can distinguish between different activities independent of the dog's location, allowing constant recording of movement in the dog's home environment, to complement the traditional clinical assessments carried out as part of the trial.
The study is being carried out to assess the efficacy of the joint mobility supplement Yumove in reducing the clinical signs of osteoarthritis. This will be the first time that the real effect of a joint supplement has been measured.
Dr. John Howie, co-founder of Lintbells, the company that makes Yumove, said: "This is the first time the real effect of a joint supplement has been measured and it will be a very fast trial. Yumove is a supplement that has been specifically formulated to include glucosamine, chondroitin and Omega 3 from green-lipped mussel, which all work together to increase joint mobility and provide an anti-inflammatory effect."
The research is being led by Dr Matthew Pead the RVC's Academic Director of Professional Assessment and Development. He said: "The results of this study will have important clinical implications for the understanding and treatment of canine OA, with the ultimate aim of advancing the treatment of this difficult and degenerative disease for the benefit of many thousands of dogs."
Any veterinary surgeon with a patient in their practice that might benefit from this study is invited to refer them. Further details are available the Clinical Investigation Centre at the Royal Veterinary College - email cic@rvc.ac.uk or phone 01707 666605.